39,147 Shares in Pacira BioSciences, Inc. (NASDAQ:PCRX) Purchased by Integrated Quantitative Investments LLC

Integrated Quantitative Investments LLC purchased a new position in Pacira BioSciences, Inc. (NASDAQ:PCRX) during the 4th quarter, HoldingsChannel reports. The institutional investor purchased 39,147 shares of the company’s stock, valued at approximately $738,000.

Other institutional investors also recently bought and sold shares of the company. Caitlin John LLC boosted its holdings in shares of Pacira BioSciences by 1,850.0% in the 4th quarter. Caitlin John LLC now owns 1,872 shares of the company’s stock valued at $35,000 after acquiring an additional 1,776 shares during the last quarter. Nisa Investment Advisors LLC boosted its holdings in Pacira BioSciences by 495.3% in the fourth quarter. Nisa Investment Advisors LLC now owns 3,304 shares of the company’s stock valued at $62,000 after purchasing an additional 2,749 shares during the last quarter. PNC Financial Services Group Inc. grew its position in Pacira BioSciences by 16.6% during the 4th quarter. PNC Financial Services Group Inc. now owns 3,597 shares of the company’s stock worth $68,000 after purchasing an additional 513 shares during the period. Virtus Investment Advisers Inc. purchased a new position in shares of Pacira BioSciences during the 3rd quarter valued at about $98,000. Finally, China Universal Asset Management Co. Ltd. raised its stake in shares of Pacira BioSciences by 10.3% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 9,790 shares of the company’s stock valued at $184,000 after buying an additional 918 shares during the last quarter. 99.73% of the stock is owned by hedge funds and other institutional investors.

Pacira BioSciences Price Performance

NASDAQ:PCRX opened at $23.10 on Friday. The stock has a 50 day moving average of $24.88 and a two-hundred day moving average of $20.29. Pacira BioSciences, Inc. has a 12 month low of $11.16 and a 12 month high of $31.67. The firm has a market cap of $1.07 billion, a P/E ratio of -11.38 and a beta of 0.70. The company has a current ratio of 2.25, a quick ratio of 1.89 and a debt-to-equity ratio of 0.51.

Wall Street Analysts Forecast Growth

Several analysts recently commented on the company. Truist Financial raised Pacira BioSciences from a “sell” rating to a “hold” rating and raised their target price for the stock from $8.00 to $25.00 in a report on Thursday, January 30th. Needham & Company LLC lifted their target price on shares of Pacira BioSciences from $30.00 to $32.00 and gave the company a “buy” rating in a report on Friday, February 28th. Royal Bank of Canada reissued a “sector perform” rating and set a $18.00 price target on shares of Pacira BioSciences in a report on Tuesday, January 14th. Barclays upped their price objective on shares of Pacira BioSciences from $17.00 to $24.00 and gave the stock an “overweight” rating in a research report on Friday, February 28th. Finally, HC Wainwright raised their target price on Pacira BioSciences from $57.00 to $70.00 and gave the company a “buy” rating in a research report on Friday, February 28th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $27.22.

Pacira BioSciences Company Profile

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.